drugset / Trial / NCT06457204

A Study in Healthy People to Compare Two Different Sifrol® Tablets

NCT06457204

Phase 1 Completed 28 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to establish the bioequivalence of Sifrol® tablets manufactured at two different sites.

Timeline

Start
2024-07-02
Primary completion
2024-08-12
Completion
2024-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 0.088 mg Oral

Indications

No indication recorded.